Spiral Therapeutics is a clinical stage company developing therapies that target hearing loss and other ear disorders.
Inspired by ophthalmology and through the use of advanced drug delivery technologies, Spiral is building a pipeline of inner ear therapeutics, a field with high unmet needs and no approved treatments. Spiral is headquartered in San Francisco, CA.
Inspired by ophthalmology and through the use of advanced drug delivery technologies, Spiral is building a pipeline of inner ear therapeutics, a field with high unmet needs and no approved treatments. Spiral is headquartered in San Francisco, CA.
Location: United States, California, South San Francisco
Total raised: $8.25M
Investors 3
| Date | Name | Website |
| - | Esperante | esperante.... |
| - | Catalio Ca... | cataliocap... |
| - | StartX | startx.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.01.2023 | - | $8.25M | Humboldt |
Mentions in press and media 12
| Date | Title | Description |
| 14.04.2026 | Spiral Therapeutics Raises $27M in Series B Funding | Spiral Therapeutics, Inc., a San Francisco, CA-based clinical-stage company developing novel therapies for inner ear disorders, raised $27M in Series B funding. The round was led by Gund Investment, with participation from Advanced Bionics,... |
| 14.04.2026 | Spiral Therapeutics: $27 Million Series B And Advanced Bionics Partnership Advance Inner Ear Therapies | Spiral Therapeutics, a clinical-stage biotechnology company developing therapies for inner ear disorders, announced the close of a $27 million Series B financing alongside a strategic research and development collaboration with Advanced Bio... |
| 30.08.2023 | Spiral Therapeutics Raises New Financing | Spiral Therapeutics, a South San Francisco, CA-based clinical-stage company focused on delivering therapies for inner ear disorders, raised an undisclosed amount in new financing. The round was led by Esperante Ventures and Ferring Ventures... |
| 09.01.2023 | Spiral Therapeutics Closes $8.25M in Financing | Spiral Therapeutics, a South San Francisco, CA-based clinical-stage company focused on delivering therapies for inner ear disorders, raised $8.25M in funding. The round was led by Savoir Capital and Catalio Capital Management with participa... |
| 07.05.2019 | Spiral Therapeutics eleva a $5,6M (€5M) la ronda de finales de 2018, acuden Inveready y el BA coreano Sunghwan Choi | 07/05/2019 SPIRAL THERAPEUTICS ELEVA A $5,6 MILLONES (€5 MILLONES) LA RONDA DE FINALES DE 2018, ACUDEN INVEREADY Y EL BUSINESS ANGEL COREANO SUNGHWAN CHOI. Spiral Therapeutics ha llevado a cabo el segundo cierre de la ronda Serie A que ab... |
| 06.05.2019 | Spiral Therapeutics Closes $5.6M Series A Financing | Spiral Therapeutics, a Brisbane, Calif.-based clinical stage pharmaceutical company delivering therapies for hearing loss, held the second closing of its $5.6M Series A financing. New investors participating in the second closing included S... |
| 06.05.2019 | Daily funding roundup - May 7th, 2019 | Indose raised $3.5M; Crusoe landed $4.5M; Spiral Therapeutics closed $5.6M Indose: Indose is a technology company in the cannabis industry with the first medicinal device that measures dosage. Indose has raised $3.5 million in Series A fund... |
| 27.12.2018 | Spiral Therapeutics Secures $3.7M in Series A Financing | Hugo Peris, founder and Chief Executive Officer of Spiral Therapeutics Spiral Therapeutics, a San Francisco, CA-based clinical stage pharmaceutical company focused on the development of therapies targeting inner ear disorders, secured $3.7m... |
| 12.12.2018 | Camden Partners Nexus co-leads $3.7M investment in pharmaceutical company treating hearing loss | Early-stage pharmaceutical company Spiral Therapeutics received $3.7 million in new investment as it looks to advance treatments for hearing loss and other inner ear disorders. The first close of the Series A round was led by Baltimore-base... |
| 12.12.2018 | Camden Partners Co-leads $3.7M Series A for Spiral Therapeutics | Spiral Therapeutics, a clinical stage pharmaceutical company focused on the development of first-in-class therapies to target inner ear disorders, has secured $3.7 million as part of a Series A financing round co-led by Savoir Capital and C... |
Show more